This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

In The News

/In The News

Abeona PACE Update: Fast Track granted by FDA for ABO-101

Today Abeona Therapeutics announced that the FDA has granted Fast Track designation to ABO-101, the investigational gene therapy approach currently being investigated in children with MPS IIIB. The phase 1/2 clinical study, ABT-002, is currently enrolling in Spain and the US though we are working to activate additional study sites. This is an important designation by the [...]

Invitation to Participate in Research Study for Canadian Patients and Families with Lysosomal Storage Diseases (LSDs)

Invitation to Participate in Research Study for Canadian Patients and Families with Lysosomal Storage Diseases (LSDs)  This study is part of the PhD Program at the Carleton University Study Title: Access to Orphan Drugs in Canada: Integrating Patient and Policy Perspectives (Study #110105).   Dear patients and families with Lysosomal Storage Diseases (LSDs): We are conducting interviews [...]

Sangamo Therapeutics announced an update on its in vivo genome editing programs: SB-913 (mucopolysaccharidosis type II, or MPS II), SB-318 (MPS I)

    Message from Christeen Moburg, Sr. Director, Patient Advocacy, Sangamo Therapeutics MPS I & MPS II We have been encouraged and heartened to see preliminary evidence of successful in vivo genome editing in our MPS I and MPSII clinical studies. However, we have determined that no additional patients will be treated at this time with first generation [...]

Search for potential participants in ongoing gene transfer clinical trials in Mucopolysaccharidosis type III (Sanfilippo A/B) and Neuronal Ceroid Lipofuscinosis (CLN) type 1

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for life- threatening paediatric rare genetic diseases. We are currently conducting clinical trials using adeno-associated virus serotype 9 (AAV9)-based vectors for correction of enzymatic defect in lysosomal storage disorders. These studies may be of interest to your patients. Other AAV-based gene therapies have [...]

Fund Development Director Position – Part-time

The Canadian MPS Society is seeking a Fund Development Director to build and manage the fundraising strategy and activities of the organization. The successful candidate will be driven, ambitious, excellent at interpersonal communications, experienced in major gift and/or foundation fundraising. Please view the attached position description. Fund Development Officer P:T Jan 2019 Email resume and cover [...]

Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)

Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A) Trial to assess efficacy on neurodevelopmental status of MPS IIIA patients CAMBRIDGE, Mass. and PARIS – Feb. 14, 2019 – Lysogene (FR0013233475 – LYS), a pioneering [...]

How to Deal with the Stress and Anxiety from Taking Care of a Child with MPS

It’s a parent’s responsibility to love and protect their children and keep them from harm’s way, allowing them to grow up strong and healthy.  That’s the normal way most people look at parenting.  But, what happens when their child is diagnosed with a chronic illness like MPS?  Aside from worry and gathering all the information and [...]

RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II)

November 7, 2018 - REGENXBIO announced that the first subject was dosed at the Children's Hospital of Pittsburgh by a medical team led by Dr. Maria Escolar, Associate Professor of Pediatrics, Director of Program for the Study of Neurodevelopment in Rare Disorders at the Children's Hospital of Pittsburgh and primary investigator for the Phase I/II clinical [...]

Please give to the 2018 Annual Fund

Proceeds from the Annual Fund raise public awareness, support our families and strengthen the leadership and overall effectiveness of the Canadian MPS Society. Donate to the Annual Fund For more information, please call 1-800-667-1846 or email info@mpssociety.ca Thank you for helping to support Canadian families affected by MPS and related diseases and advance research to find a [...]

Introducing Venture through Life

 Hello everyone! We are very pleased to welcome you our special blog Venture through Life. This project, very dear to our hearts, has been a long time in the making and we’re eager to get this journey started. We are both members of the Canadian MPS Society and have been for many years. We will be writing [...]